Heron Therapeutics, Inc.
Biopharmaceutical company focused on developing and commercializing reformulated and extended‑release versions of approved pharmacological agents for acute care and oncology supportive care. Activities include formulation development for parenteral delivery, clinical development (Phase 2/3), regulatory submissions and commercialization of FDA‑approved injectable and extended‑release products, and medical information and investigator‑initiated trial support for healthcare professionals.
Industries
Nr. of Employees
medium (51-250)
Heron Therapeutics, Inc.
Patents
Products
CINVANTI (aprepitant) injectable emulsion
A neurokinin‑1 (NK1) receptor antagonist formulated as an injectable emulsion for prevention of acute and delayed chemotherapy‑induced nausea and vomiting; available as 30‑minute infusion and 2‑minute IV push.
ZYNRELEF (bupivacaine and meloxicam) extended‑release solution
A fixed‑dose dual‑acting extended‑release local analgesic combining bupivacaine and meloxicam for instillation into the surgical wound to provide postsurgical analgesia for up to 72 hours.
SUSTOL (granisetron) extended‑release injection
A serotonin‑3 (5‑HT3) receptor antagonist in an extended‑release injectable formulation indicated for prevention of acute and delayed nausea and vomiting associated with certain chemotherapy regimens.
APONVIE (aprepitant) injectable emulsion
An injectable formulation of aprepitant indicated for prevention of postoperative nausea and vomiting (PONV); administered as a short IV infusion and bioequivalent to oral aprepitant.
SUSTOL
SUSTOL is a subcutaneous injection approved for the prevention of chemotherapy-induced nausea and vomiting (CINV).
ZYNRELEF
ZYNRELEF is indicated for postoperative pain management and is approved in the U.S., Canada, and 31 European countries.
CINVANTI (aprepitant) injectable emulsion
A neurokinin‑1 (NK1) receptor antagonist formulated as an injectable emulsion for prevention of acute and delayed chemotherapy‑induced nausea and vomiting; available as 30‑minute infusion and 2‑minute IV push.
ZYNRELEF (bupivacaine and meloxicam) extended‑release solution
A fixed‑dose dual‑acting extended‑release local analgesic combining bupivacaine and meloxicam for instillation into the surgical wound to provide postsurgical analgesia for up to 72 hours.
SUSTOL (granisetron) extended‑release injection
A serotonin‑3 (5‑HT3) receptor antagonist in an extended‑release injectable formulation indicated for prevention of acute and delayed nausea and vomiting associated with certain chemotherapy regimens.
APONVIE (aprepitant) injectable emulsion
An injectable formulation of aprepitant indicated for prevention of postoperative nausea and vomiting (PONV); administered as a short IV infusion and bioequivalent to oral aprepitant.
SUSTOL
SUSTOL is a subcutaneous injection approved for the prevention of chemotherapy-induced nausea and vomiting (CINV).
ZYNRELEF
ZYNRELEF is indicated for postoperative pain management and is approved in the U.S., Canada, and 31 European countries.
Services
Respond to medical inquiries from U.S. healthcare professionals via an online form and telephone contact; includes distribution of prescribing information and reprints.
Funding review and support for investigator‑initiated trials, medical education grants, sponsorships, and contributions focused on oncology and postoperative pain management; application forms provided online.
Provision of publications and clinical resources to support evidence‑based use of products and to inform healthcare professionals.
Respond to medical inquiries from U.S. healthcare professionals via an online form and telephone contact; includes distribution of prescribing information and reprints.
Funding review and support for investigator‑initiated trials, medical education grants, sponsorships, and contributions focused on oncology and postoperative pain management; application forms provided online.
Provision of publications and clinical resources to support evidence‑based use of products and to inform healthcare professionals.
Expertise Areas
- Clinical trial management
- Formulation development for parenteral delivery
- Extended‑release drug delivery
- Oncology supportive care (antiemetics)
Key Technologies
- Extended‑release drug delivery
- Injectable emulsion formulation
- Parenteral administration (IV push, IV infusion, subcutaneous)
- Dual‑acting local anesthetic + NSAID combination formulation